Payment overview · 2025
General Payments
$97.10
5 reported records · 4 companies
Healthcare provider profile · identity verified
Gary M Dalley, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRASELTON, GA · NPI 1629071873
Verified facts
What the public records show
CMS Open Payments records show Gary M Dalley, M.D. received $97.10 in general payments during 2025 across 5 reported records.
GlaxoSmithKline, LLC. accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.67 | 41.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.63 | 23.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.94 | 18.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.86 | 16.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.10 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $40.67 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.67 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 150 |
| Losartan Potassium | Losartan Potassium | 464 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 398 | 122 |
| Metformin Hcl | Metformin Hcl | 319 | 97 |
| Lisinopril | Lisinopril | 294 | 94 |
| Omeprazole | Omeprazole | 247 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 72 |
| Simvastatin | Simvastatin | 202 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 164 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 38 |
| Allopurinol | Allopurinol | 132 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 46 |
| Gabapentin | Gabapentin | 118 | 34 |
| Potassium Chloride | Potassium Chloride | 106 | 31 |
| Finasteride | Finasteride | 104 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 35 |
| Ozempic | Semaglutide | 97 | 16 |
| Glipizide Er | Glipizide | 90 | 25 |
| Montelukast Sodium | Montelukast Sodium | 82 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 24 |
| Meloxicam | Meloxicam | 71 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 21 |
| Jardiance | Empagliflozin | 68 | 14 |
| Alprazolam | Alprazolam | 65 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 20 |
| Atenolol | Atenolol | 62 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 14 |
| Alendronate Sodium | Alendronate Sodium | 59 | 17 |
| Eliquis | Apixaban | 59 | 12 |
| Carvedilol | Carvedilol | 58 | 18 |
| Famotidine | Famotidine | 55 | 21 |
| Metformin Hcl Er | Metformin Hcl | 53 | 16 |
| Trazodone Hcl | Trazodone Hcl | 51 | 17 |
| Clonazepam | Clonazepam | 48 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 17 |
| Glipizide | Glipizide | 46 | 16 |
| Furosemide | Furosemide | 45 | 16 |
| Synthroid | Levothyroxine Sodium | 43 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 11 |
| Januvia | Sitagliptin Phosphate | 41 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 15 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 12 |
| Buspirone Hcl | Buspirone Hcl | 36 | 13 |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Sertraline Hcl | Sertraline Hcl | 35 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Bupropion Xl | Bupropion Hcl | 33 | 13 |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 13 |
| Ramipril | Ramipril | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 24 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 24 | 24 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Celecoxib | Celecoxib | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Proctosol-Hc | Hydrocortisone | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.10 · 5 records | GlaxoSmithKline, LLC. | AREXVY, BEXSERO, Dexcom G6 Transmitter, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error